These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

565 related articles for article (PubMed ID: 16088797)

  • 21. Rotavirus vaccines: targeting the developing world.
    Glass RI; Bresee JS; Turcios R; Fischer TK; Parashar UD; Steele AD
    J Infect Dis; 2005 Sep; 192 Suppl 1():S160-6. PubMed ID: 16088799
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cost-effectiveness of a pentavalent human-bovine reassortant rotavirus vaccine for children ≤5 years of age in Taiwan.
    Itzler RF; Chen PY; Lac C; El Khoury AC; Cook JR
    J Med Econ; 2011; 14(6):748-58. PubMed ID: 21919673
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cost-effectiveness analysis of a rotavirus immunization program for the United States.
    Smith JC; Haddix AC; Teutsch SM; Glass RI
    Pediatrics; 1995 Oct; 96(4 Pt 1):609-15. PubMed ID: 7567319
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cost-effectiveness of rotavirus vaccination in Turkey.
    Koksal T; Akelma AZ; Koksal AO; Kutukoglu I; Ozdemir O; Yuksel CN; Bozkaya D; Catal F; Sari S
    J Microbiol Immunol Infect; 2017 Oct; 50(5):693-699. PubMed ID: 27107612
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Health economics of rotavirus immunization in Vietnam: potentials for favorable cost-effectiveness in developing countries.
    Tu HA; Rozenbaum MH; Coyte PC; Li SC; Woerdenbag HJ; Postma MJ
    Vaccine; 2012 Feb; 30(8):1521-8. PubMed ID: 22119590
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Rotavirus disease in Uzbekistan: cost-effectiveness of a new vaccine.
    Isakbaeva ET; Musabaev E; Antil L; Rheingans R; Juraev R; Glass RI; Bresee JS
    Vaccine; 2007 Jan; 25(2):373-80. PubMed ID: 16930784
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Impact of transmission dynamics on the cost-effectiveness of rotavirus vaccination.
    Shim E; Galvani AP
    Vaccine; 2009 Jun; 27(30):4025-30. PubMed ID: 19389452
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Disease and economic burden of rotavirus diarrhoea in India.
    Tate JE; Chitambar S; Esposito DH; Sarkar R; Gladstone B; Ramani S; Raghava MV; Sowmyanarayanan TV; Gandhe S; Arora R; Parashar UD; Kang G
    Vaccine; 2009 Nov; 27 Suppl 5():F18-24. PubMed ID: 19931713
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evaluation of cost-effectiveness of live oral pentavalent reassortant rotavirus vaccine introduction in Ghana.
    Abbott C; Tiede B; Armah G; Mahmoud A
    Vaccine; 2012 Mar; 30(15):2582-7. PubMed ID: 22321664
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Estimating the costs of implementing the rotavirus vaccine in the national immunisation programme: the case of Malawi.
    Madsen LB; Ustrup M; Hansen KS; Nyasulu PS; Bygbjerg IC; Konradsen F
    Trop Med Int Health; 2014 Feb; 19(2):177-85. PubMed ID: 24314006
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Rotavirus vaccination in northeast Brazil: a laudable intervention, but can it lead to cost-savings?
    Centenari C; Gurgel RQ; Bohland AK; Oliveira DM; Faragher B; Cuevas LE
    Vaccine; 2010 Jun; 28(25):4162-8. PubMed ID: 20417608
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Potential epidemiological and economical impact of two rotavirus vaccines in Colombia.
    De la Hoz F; Alvis N; Narváez J; Cediel N; Gamboa O; Velandia M
    Vaccine; 2010 May; 28(22):3856-64. PubMed ID: 20347057
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Rotavirus vaccination for Hong Kong children: an economic evaluation from the Hong Kong Government perspective.
    Ho AM; Nelson EA; Walker DG
    Arch Dis Child; 2008 Jan; 93(1):52-8. PubMed ID: 17855438
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Projected health benefits and costs of pneumococcal and rotavirus vaccination in Uganda.
    Tate JE; Kisakye A; Mugyenyi P; Kizza D; Odiit A; Braka F
    Vaccine; 2011 Apr; 29(17):3329-34. PubMed ID: 21241733
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cost-effectiveness of rotavirus vaccination in Kenya and Uganda.
    Sigei C; Odaga J; Mvundura M; Madrid Y; Clark AD; ;
    Vaccine; 2015 May; 33 Suppl 1():A109-18. PubMed ID: 25919149
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [A full economic evaluation of extensive vaccination against rotavirus with RIX4414 vaccine at National and Regional level in Italy].
    Vitale F; Barbieri M; Dirodi B; Vitali Rosati G; Franco E
    Ann Ig; 2013; 25(1):43-56. PubMed ID: 23435779
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The cost-effectiveness of typhoid Vi vaccination programs: calculations for four urban sites in four Asian countries.
    Cook J; Jeuland M; Whittington D; Poulos C; Clemens J; Sur D; Anh DD; Agtini M; Bhutta Z;
    Vaccine; 2008 Nov; 26(50):6305-16. PubMed ID: 18835415
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cost-effectiveness of rotavirus vaccination programs in Taiwan.
    Chang WC; Yen C; Chi CL; Wu FT; Huang YC; Lin JS; Huang FC; Tate JE; Wu HS; Hsiung CA
    Vaccine; 2013 Nov; 31(46):5458-65. PubMed ID: 24060569
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Global rotavirus surveillance: determining the need and measuring the impact of rotavirus vaccines.
    Widdowson MA; Steele D; Vojdani J; Wecker J; Parashar U
    J Infect Dis; 2009 Nov; 200 Suppl 1():S1-8. PubMed ID: 19817589
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Implementing rotavirus vaccination in Asia.
    Santosham M; Nelson EA; Bresee JS
    Vaccine; 2007 Nov; 25(44):7711-6. PubMed ID: 17881099
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 29.